title: Epilepsy after neuroimaging normalization in a woman with tacrolimus-related posterior reversible encephalopathy syndrome.
abstract: Posterior reversible encephalopathy syndrome (PRES) is known to occur after solid organ transplantation, and is caused by immunosuppressive agents such as tacrolimus. PRES onset usually occurs within the first 2months after liver transplantation. Clinical findings include seizures, headache, focal neurological deficits, visual disturbances, and altered mental status. These are associated with characteristic imaging features of subcortical white matter lesions on brain MRI. Atypical localizations of this posterior leukoencephalopathy have been reported. Expeditious recognition of the syndrome may lead to a complete recovery. Abnormalities of EEG during follow-up might be associated with unfavorable seizure outcome, even when neuroimaging changes resolve. We report a case of late-onset PRES with atypical localization following liver transplantation. The patient developed epilepsy despite resolution of MRI lesions at 8 months of follow-up. EEG was a prognostic factor of seizure persistence, suggesting an incomplete recovery of brain lesions in contrast to neuroimaging findings.
authors.affiliation: Department of Neuroscience, University of Pisa, Pisa, Italy. baldinimariella@libero.it
authors.forename: Mariella
authors.initials: M
authors.lastname: Baldini
authors.forename: Emanuele
authors.initials: E
authors.lastname: Bartolini
authors.forename: Sara
authors.initials: S
authors.lastname: Gori
authors.forename: Enrica
authors.initials: E
authors.lastname: Bonanni
authors.forename: Mirco
authors.initials: M
authors.lastname: Cosottini
authors.forename: Alfonso
authors.initials: A
authors.lastname: Iudice
authors.forename: Luigi
authors.initials: L
authors.lastname: Murri
mesh_terms: D004569:Electroencephalography / Q000379:methods; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced*; D005260:Female; D005500:Follow-Up Studies; D005625:Frontal Lobe / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging / Q000379:methods; D016559:Tacrolimus / Q000009:adverse effects*; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus